We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microchip to Replace Research Animals

By Biotechdaily staff writers
Posted on 04 Oct 2005
To reduce the number of animals used in the development of new drugs, researchers have developed a microchip that serves as an in vivo surrogate, reducing the use of animals, speeding drug development, lowering costs, and increasing the efficiency of preclinical testing.

The 22 mm microfluidic circuit, developed by scientists at Cornell University (Ithaca, NY, USA), is designed to assess the effects of a new drug compound in animals or humans in a high-throughput manner. More...
The idea is to run the chip as though it were a rat or dog and to be able to tell if this particular animal is going to be appropriate for further testing.

The microfluidic unit contains an arrangement of interconnected "organ” or "tissue” compartments. Each contains a culture of living cells from animals or humans to mimic the function of particular organs and tissues, such as liver, heart, lung, or fat cells. The compartments are connected by micro channels through which a blood substitute, or culture medium, circulates. The test drug is added to this culture medium and circulates around the device. Its effects on the cells within each compartment can then be measured.

"What we are trying to do is to mimic what goes on in the body on a micro scale,” explained Dr. Leslie Benet, professor of biopharmaceutical sciences at the University of California San Francisco (USA; www.ucsf.edu). Dr. Benet believes the chip will save a lot of animal studies but will not eliminate them. "At the moment, we don't know which animal is going to be useful. So the industry often carries out animal tests that turn out not to be predictive at all.”

The chip should provide data on how a drug is handled by the body, how it is eliminated, and how it is metabolized. According to Dr. Benet, by assessing a drug's effects on different tissues and by being able to mimic the normal interplay of enzymes and transporters, the microchip should be more efficient than standard cell culture experiments. Dr. Benet is chairman of the scientific advisory board for a new corporation founded to commercialize the microchip.




Related Links:
U. California, SF
Cornell Univ

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.